Don't think twice it's all right: Tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients

Per Damkier*

*Corresponding author for this work

Research output: Contribution to journalComment/debateResearchpeer-review

Abstract

Letter in resonse to: Del Re M, Rofi E, Citi V, Fidilio L, Danesi R. Should CYP2D6 be genotyped when treating with tamoxifen? Pharmacogenomics 17(18), 1967-1969 (2016).

Original languageEnglish
JournalPharmacogenomics
Volume18
Issue number8
Pages (from-to)753-754
ISSN1462-2416
DOIs
Publication statusPublished - Jun 2017

Keywords

  • Antineoplastic Agents, Hormonal/therapeutic use
  • Breast Neoplasms/drug therapy
  • Cytochrome P-450 CYP2D6/genetics
  • Female
  • Genotype
  • Humans
  • Meta-Analysis as Topic
  • Pharmacogenetics/methods
  • Tamoxifen/therapeutic use

Fingerprint

Dive into the research topics of 'Don't think twice it's all right: Tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients'. Together they form a unique fingerprint.

Cite this